PA8646201A1 - Uso de epotilonas en el tratamiento de metastasis osea - Google Patents
Uso de epotilonas en el tratamiento de metastasis oseaInfo
- Publication number
- PA8646201A1 PA8646201A1 PA20058646201A PA8646201A PA8646201A1 PA 8646201 A1 PA8646201 A1 PA 8646201A1 PA 20058646201 A PA20058646201 A PA 20058646201A PA 8646201 A PA8646201 A PA 8646201A PA 8646201 A1 PA8646201 A1 PA 8646201A1
- Authority
- PA
- Panama
- Prior art keywords
- treatment
- epotilones
- osea
- metastasis
- bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA ACTUAL INVENCIÓN SE RELACIONA CON EL USO DE EPOTHILONES EN EL TRATAMIENTO DE LAS METÁSTASIS DEL HUESO Y LOS TUMORES O LOS CÁNCERES DEL HUESO, MÁS PARTICULARMENTE EN TRATAR, PREVINIENDO O ALIVIANDO LA METÁSTASIS DEL HUESO EN UN PACIENTE DEL CÁNCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090377A EP1640004A1 (en) | 2004-09-24 | 2004-09-24 | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8646201A1 true PA8646201A1 (es) | 2006-11-09 |
Family
ID=34928830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20058646201A PA8646201A1 (es) | 2004-09-24 | 2005-09-22 | Uso de epotilonas en el tratamiento de metastasis osea |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1640004A1 (es) |
JP (1) | JP2008514569A (es) |
KR (1) | KR20070054214A (es) |
CN (1) | CN101065126A (es) |
AR (1) | AR051035A1 (es) |
AU (1) | AU2005287477A1 (es) |
BR (1) | BRPI0516080A (es) |
CA (1) | CA2580215A1 (es) |
CR (1) | CR9064A (es) |
EC (1) | ECSP077390A (es) |
GT (1) | GT200500267A (es) |
IL (1) | IL181785A0 (es) |
MX (1) | MX2007003503A (es) |
NO (1) | NO20072099L (es) |
PA (1) | PA8646201A1 (es) |
PE (1) | PE20060695A1 (es) |
RU (1) | RU2007115162A (es) |
TW (1) | TW200626150A (es) |
UY (1) | UY29136A1 (es) |
WO (1) | WO2006032537A2 (es) |
ZA (1) | ZA200703306B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1930004A1 (en) * | 2006-12-08 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Use of epothilones in the treatment of osteoporosis and related diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
CA2352505C (en) * | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
AR023792A1 (es) * | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
CA2385528C (en) * | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
JP2004508810A (ja) * | 2000-04-28 | 2004-03-25 | コーサン バイオサイエンシーズ, インコーポレイテッド | ポリケチドの生成 |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
WO2002080846A2 (en) * | 2001-04-03 | 2002-10-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003077903A1 (en) * | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
DE60328772D1 (de) * | 2002-05-01 | 2009-09-24 | Novartis Ag | Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen |
EP1581218A1 (en) * | 2002-12-05 | 2005-10-05 | Schering AG | Epothilone analogs for site specific delivery in the treatment of proliferative diseases |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1475105A1 (en) * | 2003-05-09 | 2004-11-10 | Schering AG | Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
EP1641449A1 (en) * | 2003-06-27 | 2006-04-05 | Novartis AG | Cancer treatment with epothilones |
CA2537057A1 (en) * | 2003-09-02 | 2005-03-10 | Novartis Ag | Cancer treatment with epothilones |
-
2004
- 2004-09-24 EP EP04090377A patent/EP1640004A1/en not_active Withdrawn
-
2005
- 2005-09-22 AU AU2005287477A patent/AU2005287477A1/en not_active Abandoned
- 2005-09-22 CA CA002580215A patent/CA2580215A1/en not_active Abandoned
- 2005-09-22 MX MX2007003503A patent/MX2007003503A/es not_active Application Discontinuation
- 2005-09-22 WO PCT/EP2005/010400 patent/WO2006032537A2/en active Application Filing
- 2005-09-22 RU RU2007115162/15A patent/RU2007115162A/ru not_active Application Discontinuation
- 2005-09-22 BR BRPI0516080-4A patent/BRPI0516080A/pt not_active IP Right Cessation
- 2005-09-22 CN CNA2005800402761A patent/CN101065126A/zh active Pending
- 2005-09-22 JP JP2007532855A patent/JP2008514569A/ja active Pending
- 2005-09-22 EP EP05788787A patent/EP1809281A2/en not_active Withdrawn
- 2005-09-22 PA PA20058646201A patent/PA8646201A1/es unknown
- 2005-09-22 KR KR1020077006651A patent/KR20070054214A/ko not_active Application Discontinuation
- 2005-09-23 GT GT200500267A patent/GT200500267A/es unknown
- 2005-09-23 TW TW094133125A patent/TW200626150A/zh unknown
- 2005-09-23 UY UY29136A patent/UY29136A1/es not_active Application Discontinuation
- 2005-09-23 PE PE2005001103A patent/PE20060695A1/es not_active Application Discontinuation
- 2005-09-26 AR ARP050104007A patent/AR051035A1/es unknown
-
2007
- 2007-03-07 IL IL181785A patent/IL181785A0/en unknown
- 2007-04-11 EC EC2007007390A patent/ECSP077390A/es unknown
- 2007-04-19 CR CR9064A patent/CR9064A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072099A patent/NO20072099L/no not_active Application Discontinuation
- 2007-04-23 ZA ZA200703306A patent/ZA200703306B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200703306B (en) | 2010-06-30 |
UY29136A1 (es) | 2006-04-28 |
NO20072099L (no) | 2007-04-23 |
CN101065126A (zh) | 2007-10-31 |
EP1640004A1 (en) | 2006-03-29 |
AR051035A1 (es) | 2006-12-13 |
PE20060695A1 (es) | 2006-08-03 |
CR9064A (es) | 2007-10-01 |
KR20070054214A (ko) | 2007-05-28 |
ECSP077390A (es) | 2007-05-30 |
AU2005287477A1 (en) | 2006-03-30 |
WO2006032537A2 (en) | 2006-03-30 |
TW200626150A (en) | 2006-08-01 |
RU2007115162A (ru) | 2008-11-20 |
WO2006032537A3 (en) | 2006-05-04 |
GT200500267A (es) | 2006-06-06 |
BRPI0516080A (pt) | 2008-08-19 |
IL181785A0 (en) | 2007-07-04 |
MX2007003503A (es) | 2007-08-17 |
EP1809281A2 (en) | 2007-07-25 |
JP2008514569A (ja) | 2008-05-08 |
CA2580215A1 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600092A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
TW200612918A (en) | Lonidamine analogs | |
UY28258A1 (es) | Tratamiento terapeutico | |
SV2005001973A (es) | Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500) | |
DE602005026508D1 (de) | Monozyklische heterozyklen als kinase-hemmer | |
DK3059322T3 (da) | Genekspressionsmarkører for brystcancerprognose | |
MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
ATE461217T1 (de) | Glp-1-verbindungen | |
AR028296A1 (es) | Metodos sinergisticos y composiciones para el tratamiento del cancer | |
DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
CY1112743T1 (el) | Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους | |
CL2007002382A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel. | |
NO20055741D0 (no) | Nye kjemiske forbindelser | |
ATE425982T1 (de) | Thienopyrimidin-derivate als kaliumkanal- inhibitoren | |
CY1109758T1 (el) | Ηλεκτρομαγνητικη διεγερση ασθενων με οστεοπορωση | |
NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
HRP20090513T1 (en) | S-mirtazapine for the treatment of hot flush | |
MX2007000360A (es) | Marcadores moleculares de pronostico. | |
SE0302304D0 (sv) | Novel compounds | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
ATE407937T1 (de) | Rutheniumkomplexe mit antikrebswirkung | |
PA8646201A1 (es) | Uso de epotilonas en el tratamiento de metastasis osea | |
EE200200479A (et) | Eksemestaani kasutamine rinnavähi ravis | |
DE602006009840D1 (de) | Verwendung von prolactin in der prophylaktischen krebstherapie |